156 related articles for article (PubMed ID: 23453679)
1. Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer.
Rajagopalan MS; Kannan N; Kim H; Houser CJ; Beriwal S
Brachytherapy; 2013; 12(3):248-53. PubMed ID: 23453679
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy.
Kim H; Rajagopalan MS; Houser C; Beriwal S
Brachytherapy; 2014; 13(3):263-7. PubMed ID: 24080298
[TBL] [Abstract][Full Text] [Related]
5. Differences in urethral dosimetry between CT and MR imaging in multichannel vaginal cylinder brachytherapy.
Chen KS; Glaser SM; Kim H; Beriwal S
Brachytherapy; 2017; 16(5):964-967. PubMed ID: 28694115
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional image-based high-dose-rate interstitial brachytherapy for vaginal cancer.
Beriwal S; Rwigema JC; Higgins E; Kim H; Houser C; Sukumvanich P; Olawaiye A; Richard S; Kelley JL; Edwards RP; Krivak TC
Brachytherapy; 2012; 11(3):176-80. PubMed ID: 21665553
[TBL] [Abstract][Full Text] [Related]
7. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
8. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
[TBL] [Abstract][Full Text] [Related]
10. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy.
Cunha JA; Pouliot J; Weinberg V; Wang-Chesebro A; Roach M; Hsu IC
Brachytherapy; 2012; 11(5):348-53. PubMed ID: 21937284
[TBL] [Abstract][Full Text] [Related]
11. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
12. Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: clinical outcomes and dose--volume histogram analysis.
Thibault I; Lavallée MC; Aubin S; Laflamme N; Vigneault E
Brachytherapy; 2012; 11(3):181-91. PubMed ID: 21862418
[TBL] [Abstract][Full Text] [Related]
13. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
[TBL] [Abstract][Full Text] [Related]
14. HDR brachytherapy for the reirradiation of cervical and vaginal cancer: analysis of efficacy and dosage delivered to organs at risk.
Zolciak-Siwinska A; Bijok M; Jonska-Gmyrek J; Kawczynska M; Kepka L; Bujko K; Michalski W
Gynecol Oncol; 2014 Jan; 132(1):93-7. PubMed ID: 24161366
[TBL] [Abstract][Full Text] [Related]
15. Relationship of Urethral Dose and Genitourinary Toxicity Among Patients Receiving Vaginal High Dose Rate Interstitial Brachytherapy.
Cozma AI; Martell K; Ravi A; Barnes E; Donovan E; Paudel M; Leung E; Taggar A
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):773-779. PubMed ID: 34092463
[TBL] [Abstract][Full Text] [Related]
16. Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer.
Vargo JA; Kim H; Houser CJ; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
Brachytherapy; 2015; 14(1):9-15. PubMed ID: 25456026
[TBL] [Abstract][Full Text] [Related]
17. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
18. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: a matched case-control study.
Earley JJ; Abdelbaky AM; Cunningham MJ; Chadwick E; Langley SE; Laing RW
Radiother Oncol; 2012 Aug; 104(2):187-91. PubMed ID: 22841018
[TBL] [Abstract][Full Text] [Related]
19. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
20. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
